Suppr超能文献

韩国儿童呼吸道合胞病毒预防策略:当前方法与新出现选择的综述

RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options.

作者信息

Kim Hyun Jung, Choi Sujin, Choe Young June

机构信息

Medical Affairs, Sanofi, Seoul, Korea.

Allergy Immunology Center, Korea University, Seoul, Korea.

出版信息

Infect Chemother. 2025 Mar;57(1):31-37. doi: 10.3947/ic.2024.0122.

Abstract

Respiratory syncytial virus (RSV) poses a significant threat to infants and young children in Korea and globally. Current preventive measures, such as palivizumab, have limitations, necessitating the exploration of new strategies. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising option for protecting all infants from RSV. Clinical trials and real-world evidence support its effectiveness in reducing RSV-related hospitalizations. The economic burden of RSV infection in Korea underscores the need for cost-effective interventions. While several RSV vaccines are under development, none are currently available in Korea. Maternal immunization programs and vaccines for older infants offer potential avenues for expanding protection. This review highlights the evolving landscape of RSV prevention, with a shift towards nirsevimab and future vaccines. Further research is crucial to understand the long-term consequences of RSV infection and develop comprehensive prevention strategies tailored to the Korean population.

摘要

呼吸道合胞病毒(RSV)对韩国及全球的婴幼儿构成重大威胁。目前的预防措施,如帕利珠单抗,存在局限性,因此有必要探索新的策略。Nirsevimab是一种长效单克隆抗体,已成为保护所有婴儿免受RSV感染的有前景的选择。临床试验和真实世界证据支持其在减少RSV相关住院方面的有效性。RSV感染在韩国造成的经济负担凸显了采取具有成本效益的干预措施的必要性。虽然几种RSV疫苗正在研发中,但韩国目前尚无可用疫苗。母体免疫计划和针对较大婴儿的疫苗为扩大保护范围提供了潜在途径。本综述强调了RSV预防格局的不断演变,正朝着Nirsevimab和未来疫苗的方向发展。进一步的研究对于了解RSV感染的长期后果以及制定针对韩国人群的综合预防策略至关重要。

相似文献

1
RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options.
Infect Chemother. 2025 Mar;57(1):31-37. doi: 10.3947/ic.2024.0122.
2
RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
Front Immunol. 2022 Apr 28;13:880368. doi: 10.3389/fimmu.2022.880368. eCollection 2022.
3
The recent landscape of RSV vaccine research.
Ther Adv Vaccines Immunother. 2025 Jan 10;13:25151355241310601. doi: 10.1177/25151355241310601. eCollection 2025.
4
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.
Vaccines (Basel). 2024 Nov 25;12(12):1317. doi: 10.3390/vaccines12121317.
8
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Aug 30;42(21):126164. doi: 10.1016/j.vaccine.2024.126164. Epub 2024 Jul 30.
9
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants.
Clin Drug Investig. 2025 Jun;45(6):347-361. doi: 10.1007/s40261-025-01437-8. Epub 2025 May 3.
10
Summary of the National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) in Infants.
Can Commun Dis Rep. 2025 Apr 3;51(4):113-118. doi: 10.14745/ccdr.v51i04a01. eCollection 2025 Apr.

引用本文的文献

1
2
Reply: Response to RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options.
Infect Chemother. 2025 Jun;57(2):333-334. doi: 10.3947/ic.2025.0039. Epub 2025 May 2.
3
Response to RSV Prevention Strategies in Korean Children: A Review of Current Approaches and Emerging Options.
Infect Chemother. 2025 Jun;57(2):331-332. doi: 10.3947/ic.2025.0024. Epub 2025 May 2.

本文引用的文献

1
Seasonality of common respiratory viruses: Analysis of nationwide time-series data.
Respirology. 2024 Nov;29(11):985-993. doi: 10.1111/resp.14818. Epub 2024 Aug 12.
9
Incidence, prevalence, and pattern of medical service utilization of children's rare lung diseases in South Korea.
Pediatr Pulmonol. 2024 May;59(5):1305-1312. doi: 10.1002/ppul.26906. Epub 2024 Feb 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验